Vanda Pharmaceuticals Book Value 2011-2026 | VNDA

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Vanda Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
327 M	539 M	545 M	527 M	505 M	453 M	411 M	275 M	131 M	131 M	133 M	161 M	44.1 M	9.9 M	33.5 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
545 M	9.9 M	282 M

Quarterly Book Value Vanda Pharmaceuticals

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
486 M	511 M	539 M	541 M	543 M	-	545 M	543 M	540 M	536 M	527 M	516 M	-	502 M	505 M	493 M	481 M	468 M	453 M	453 M	453 M	453 M	411 M	411 M	411 M	411 M	275 M	275 M	275 M	275 M	131 M	131 M	131 M	131 M	131 M	131 M	131 M	131 M	133 M	133 M	133 M	133 M	161 M	161 M	161 M	161 M	44.1 M	44.1 M	44.1 M	44.1 M	9.9 M	9.9 M	9.9 M	9.9 M	33.5 M	33.5 M	33.5 M	33.5 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
545 M	9.9 M	275 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
Benitec Biopharma BNTC	97.3 M	$ 10.98	-4.52 %	$ 452 M	USA
Ascendis Pharma A/S ASND	-163 M	$ 221.88	-0.87 %	$ 5 B	Danmark
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Milestone Pharmaceuticals MIST	41.8 M	$ 1.36	-20.0 %	$ 45.5 M	Canada
Pharming Group N.V. PHAR	-191 M	$ 15.36	-0.71 %	$ 7.59 B	Niderland
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Inventiva S.A. IVA	-107 M	$ 5.78	-4.3 %	$ 138 M	France
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Tiziana Life Sciences PLC TLSA	3.94 M	$ 1.21	-3.97 %	$ 71.5 M	Britain
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
PainReform Ltd. PRFX	1.82 M	$ 2.28	-0.44 %	$ 1.03 M	Israel
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	5.36 M	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	54.4 M	-	10.36 %	$ 9.8 M	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Assembly Biosciences ASMB	207 M	$ 28.46	3.45 %	$ 319 M	USA
Avenue Therapeutics ATXI	1.86 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	427 M	$ 1.37	-4.2 %	$ 350 M	Britain
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Axsome Therapeutics AXSM	88.3 M	$ 156.92	-1.23 %	$ 7.81 B	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
AbCellera Biologics ABCL	967 M	$ 3.4	-3.68 %	$ 1.02 B	Canada
Atreca BCEL	78.4 M	-	-11.76 %	$ 5.79 M	USA
BioDelivery Sciences International BDSI	188 M	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	4.36 B	-	0.49 %	$ 251 B	Cayman-islands
BioMarin Pharmaceutical BMRN	6.09 B	$ 54.13	-1.64 %	$ 10.4 B	USA
Calithera Biosciences CALA	49.1 M	-	-10.95 %	$ 876 K	USA
Cara Therapeutics CARA	57.1 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	286 M	-	-	$ 3.74 B	USA
Bellerophon Therapeutics BLPH	2.53 M	-	-74.18 %	$ 955 K	USA
Compugen Ltd. CGEN	132 M	$ 2.09	-0.95 %	$ 195 M	Israel
Coherus BioSciences CHRS	61 M	$ 1.52	-5.59 %	$ 178 M	USA
Checkpoint Therapeutics CKPT	-12.6 M	-	-	$ 169 M	USA
Clovis Oncology CLVS	-279 M	-	-7.23 %	$ 13 M	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Burford Capital Limited BUR	1.66 B	$ 7.7	-5.87 %	$ 1.29 B	Britain
Corbus Pharmaceuticals Holdings CRBP	148 M	$ 8.6	-3.8 %	$ 115 M	USA
Curis CRIS	-6 M	$ 0.77	1.89 %	$ 4.86 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA